Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director · President and CEO · 10% owner | July 06, 2026 | July 09, 2026 |
| Radius Health, Inc.RDUS · Entity 124173 | Director | February 17, 2017 | February 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PUMA BIOTECHNOLOGY, INC.
Report date July 06, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,261,671 |
Reported balance
After 2026-07-06 transaction · row 1
1 source rowRow 1 · 2026-07-06 · Sale · Disposed 44,058 · Balance 7,261,671 F1: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020.
Radius Health, Inc.
Report date February 17, 2017 · Filed February 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.65 · Expires 2027-02-16 | Direct | 27,500 |
Reported balance
After 2017-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-17 · Grant · Acquired 27,500 · Balance 27,500 F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2026 Filed Jul 9, 2026 00:21 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 44,058 | $8.26 | $364,051.25 |
DisclosureSEC source: 0001437749-26-023079 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,261,671 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020. Read SEC document |
| February 18, 2026 Filed Feb 21, 2026 01:29 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 227,474 | $0.00 Strike: $6.68 | $0.00 |
DisclosureSEC source: 0001437749-26-004948 · rdgdoc.xml · derivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,474 Underlying: Common Stock · 227,474 shares Expires 2036-02-17 F2 · derivative.exercise_date: Subject to the Reporting Person's continued status as an Employee of the Company, the Options shall vest and become exercisable with respect to one-fourth (1/4th) of the shares of Common Stock subject thereto on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events. Read SEC document |
| February 18, 2026 Filed Feb 21, 2026 01:29 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 159,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-004948 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,305,729 F1 · security: Represents the grant of Restricted Stock Units ('RSUs"). Subject to the Reporting Person's continued status as an Employee of the Company, the RSUs shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events. F1 · shares: Represents the grant of Restricted Stock Units ('RSUs"). Subject to the Reporting Person's continued status as an Employee of the Company, the RSUs shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events. F1 · price: Represents the grant of Restricted Stock Units ('RSUs"). Subject to the Reporting Person's continued status as an Employee of the Company, the RSUs shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2026, January 1, 2027, July 1, 2027 and January 1, 2028, subject to acceleration in certain events. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 01:27 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 18,012 | $5.88 | $105,892.55 |
DisclosureSEC source: 0001437749-26-000924 · rdgdoc.xml · nonDerivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,145,951 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-17-2020 Read SEC document |
| January 06, 2026 Filed Jan 9, 2026 01:27 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 16,938 | $5.84 | $98,985.67 |
DisclosureSEC source: 0001437749-26-000924 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,163,963 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-17-2020 Read SEC document |
| July 09, 2025 Filed Jul 11, 2025 00:49 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 21,580 | $3.54 | $76,285.30 |
DisclosureSEC source: 0001437749-25-022547 · rdgdoc.xml · nonDerivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,180,901 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-17-2020 Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:49 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 25,592 | $3.53 | $90,416.54 |
DisclosureSEC source: 0001437749-25-022547 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,202,481 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 12-17-2020 Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 23:51 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 274,622 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001437749-25-003454 · rdgdoc.xml · derivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,622 Underlying: Common Stock · 274,622 shares Expires 2035-02-06 F2 · derivative.exercise_date: Subject to Optionee's continued status as an Employee of the Company, Options shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares (as defined in the Plan) subject thereto on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to acceleration in certain events. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 23:51 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 198,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-003454 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,228,073 F1 · shares: Subject to Grantee's continued status as an Employee of the Company, the Restricted Stock Units ("RSUs") that shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2025, January 1, 2026, July 1, 2026 and January 1, 2027, subject to acceleration in certain events. Read SEC document |
| January 02, 2025 Filed Jan 4, 2025 00:12 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 33,841 | $3.15 | $106,656.68 |
DisclosureSEC source: 0001437749-25-000359 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,029,674 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.2101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 17, 2024 Filed Jul 18, 2024 22:50 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 21,920 | $3.70 | $81,128.11 |
DisclosureSEC source: 0001437749-24-023014 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,063,515 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.6001 to $3.8901, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 01:10 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 18,885 | $3.27 | $61,725.62 |
DisclosureSEC source: 0001437749-24-022061 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,085,435 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.2601 to $3.3101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 01:01 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 9,047 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001437749-24-008575 · rdgdoc.xml · derivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,047 Underlying: Common Stock · 9,047 shares Expires 2034-03-14 F1 · shares: Reflects supplemental annual equity awards due to an administrative error in the calculations used to determine the original number of shares underlying the annual equity awards. F3 · derivative.exercise_date: Subject to Optionee's continued status as an Employee of the Company, Options shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares subject thereto on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to acceleration in certain events. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 01:01 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 6,577 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-008575 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,104,320 F1 · shares: Reflects supplemental annual equity awards due to an administrative error in the calculations used to determine the original number of shares underlying the annual equity awards. F2 · shares: Subject to Grantee's continued status as an Employee of the Company, the Restricted Stock Units ("RSUs") shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to acceleration in certain events. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:58 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 222,573 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0001437749-24-004211 · rdgdoc.xml · derivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,573 Underlying: Common Stock · 222,573 shares Expires 2034-02-11 F2 · derivative.exercise_date: Subject to Optionee's continued status as an Employee of the Company, Options shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares (as defined in the Plan) subject thereto on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to acceleration in certain events. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 22:58 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 160,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004211 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,097,743 F1 · shares: Subject to Grantee's continued status as an Employee of the Company, the Restricted Stock Units ("RSUs") shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to acceleration in certain events. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 23:56 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 41,396 | $4.49 | $185,698.32 |
DisclosureSEC source: 0001437749-24-000770 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,936,947 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.3601 to $4.7101, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 23:03 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 60,698 | $3.31 | $200,983.22 |
DisclosureSEC source: 0001437749-23-019519 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,978,343 F1 · kind: Adoption date of referenced 10b5-1(c) sell to cover program is: 12-17-2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.24 to $3.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:39 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 258,924 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001437749-23-003371 · rdgdoc.xml · derivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,924 Underlying: Common Stock · 258,924 shares Expires 2033-02-09 F2 · derivative.exercise_date: Subject to Optionee's continued status as an Employee of the Company, Options shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares (as defined in the Plan) subject thereto on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to acceleration in certain events. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:39 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 186,403 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-003371 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,039,041 F1 · shares: Subject to Grantee's continued status as an Employee of the Company, the Restricted Stock Units ("RSUs") shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2023, January 1, 2024, July 1, 2024 and January 1, 2025, subject to acceleration in certain events. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:29 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 27,241 | $4.18 | $113,810.17 |
DisclosureSEC source: 0001437749-23-000512 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,852,638 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $4.1922, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 00:58 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 568,181 | $4.40 | $2,499,996.40 |
DisclosureSEC source: 0001437749-22-028940 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,879,879 F1 · price: On December 9, 2022, the Issuer entered into a Securities Purchase Agreement with the Reporting Person, pursuant to which these shares were purchased by the Reporting Person at the closing on December 12, 2022 for $4.40 per share. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:37 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,251 | $4.50 | $5,626.75 |
DisclosureSEC source: 0001437749-22-028564 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,311,698 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.4601 to $4.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 20:17 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,242 | $2.25 | $2,794.50 |
DisclosureSEC source: 0001437749-22-026038 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,312,949 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:32 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,260 | $2.34 | $2,942.60 |
DisclosureSEC source: 0001437749-22-023673 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,314,191 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.33 to $2.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 20:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,254 | $2.59 | $3,247.36 |
DisclosureSEC source: 0001437749-22-021980 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,315,451 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.565 to $2.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 22:42 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,247 | $2.89 | $3,603.83 |
DisclosureSEC source: 0001437749-22-018958 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,316,705 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. Read SEC document |
| July 05, 2022 Filed Jul 8, 2022 00:21 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 26,140 | $2.63 | $68,787.41 |
DisclosureSEC source: 0001437749-22-016852 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,317,952 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 21:01 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,200 | $1.94 | $2,332.92 |
DisclosureSEC source: 0001437749-22-014429 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,344,092 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. Read SEC document |
| May 03, 2022 Filed May 4, 2022 22:37 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,263 | $2.32 | $2,930.29 |
DisclosureSEC source: 0001437749-22-010922 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,345,292 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 21:41 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,198 | $3.08 | $3,687.44 |
DisclosureSEC source: 0001437749-22-008339 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,346,555 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 23:58 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 1,792,114 | $2.79 | $4,999,998.06 |
DisclosureSEC source: 0001437749-22-006207 · rdgdoc.xml · nonDerivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,347,753 F2 · price: On March 8, 2022, the Issuer entered into a Securities Purchase Agreement with certain purchasers, including the Reporting Person. Shares were purchased at $2.79 per share and issued at closing on March 10, 2022. Read SEC document |
| March 03, 2022 Filed Mar 14, 2022 23:58 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 241,176 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001437749-22-006207 · rdgdoc.xml · derivative · entry 3 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,176 Underlying: Common Stock · 241,176 shares Expires 2032-03-02 F3 · derivative.exercise_date: Subject to the Optionee's continued status as an Employee, the Option shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares (as defined in the Plan) subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024, subject to acceleration in certain events. Read SEC document |
| March 03, 2022 Filed Mar 14, 2022 23:58 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCommon Stock | 168,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-006207 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,555,639 F1 · shares: Subject to the Grantee's continued status as an Employee, the Restricted Stock Units shall vest with respect to one-fourth (1/4th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024, subject to acceleration in certain events. Read SEC document |
| March 02, 2022 Filed Mar 4, 2022 22:07 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,294 | $2.26 | $2,919.39 |
DisclosureSEC source: 0001437749-22-005301 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,386,815 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:29 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,316 | $2.46 | $3,238.68 |
DisclosureSEC source: 0001437749-22-002408 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,388,109 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:12 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 22,875 | $3.19 | $72,923.21 |
DisclosureSEC source: 0001437749-22-000446 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,389,425 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.17 to $3.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 23:31 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,837 | $2.90 | $5,327.30 |
DisclosureSEC source: 0001437749-21-027952 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,412,300 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 22:17 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,795 | $5.63 | $10,111.95 |
DisclosureSEC source: 0001209191-21-062777 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,414,137 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 21:04 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCommon Stock | 1,858 | $6.15 | $11,433.20 |
DisclosureSEC source: 0001437749-21-023375 · rdgdoc.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,415,932 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 02, 2021 Filed Sep 4, 2021 01:27 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,764 | $7.60 | $13,402.87 |
DisclosureSEC source: 0001209191-21-054918 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,417,790 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.59 to $7.6039, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 21:45 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,764 | $7.53 | $13,285.74 |
DisclosureSEC source: 0001209191-21-049423 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,419,554 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 02, 2021 Filed Jul 6, 2021 23:42 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 5,332 | $8.84 | $47,121.02 |
DisclosureSEC source: 0001209191-21-045683 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,421,318 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:49 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,757 | $10.74 | $18,877.38 |
DisclosureSEC source: 0001209191-21-038287 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,426,650 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.738 to $10.7640, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:34 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,758 | $9.01 | $15,846.61 |
DisclosureSEC source: 0001209191-21-030343 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,428,407 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.8775 to $9.9000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 21:48 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,584 | $9.80 | $15,527.79 |
DisclosureSEC source: 0001209191-21-025720 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,430,165 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:33 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,238 | $10.14 | $12,555.55 |
DisclosureSEC source: 0001209191-21-017823 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,431,749 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 23:16 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 210,944 | $0.00 Strike: $12.02 | $0.00 |
DisclosureSEC source: 0001209191-21-012518 · doc4.xml · derivative · entry 2 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,944 Underlying: COMMON STOCK · 210,944 shares Expires 2031-02-16 F3 · derivative.exercise_date: Subject to the Optionee's continued status as an Employee, the Option shall vest and become exercisable with respect to (i) one-third (1/3rd) of the Shares subject thereto on the first anniversary of January 1, 2021 (the "Vesting Commencement Date"), and (ii) one-sixth (1/6th) of the Shares subject thereto on each of July 1, 2022, January 1, 2023, July 1, 2023, and January 1, 2024; provided, however, that if the Optionee experiences a Termination of Service by the Company without Cause or by the Optionee with Good Reason (each as defined in Mr. Auerbach's employment agreement), in either case, during the period beginning sixty (60) days prior to and ending eighteen (18) months after the occurrence of a Change in Control, then (subject to timely executing and not revoking the Release Agreement (as defined in the employment agreement)) (i) the Option shall vest and become exercisable in full on the later to occur of such termination or the Change in Control, and (continued in footnote 4) F4 · derivative.exercise_date: (continued from footnote 3 above) (ii) the Option shall remain exercisable until the earlier to occur of the first anniversary of such termination or the Expiration Date. Unless otherwise defined herein, the terms used herein have the same defined meanings as in the Stock Option Agreement. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 23:16 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 149,951 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-012518 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,432,987 F1 · shares: Subject to the Grantee's continued status as an Employee, the Restricted Stock Units shall vest with respect to (i) one-third (1/3rd) of the Restricted Stock Units on the first anniversary of the vesting commencement date of January 1, 2021 (the "Vesting Commencement Date"), and (ii) one-sixth (1/6th) of the Restricted Stock Units on each of July 1, 2022, January 1, 2023, July 1, 2023 and January 1, 2024; provided, however, that if the Grantee experiences a Termination of Service by the Company without Cause or by the Grantee with Good Reason (each as defined in Mr. Auerbach's employment agreement), in either case, during the period beginning sixty (60) days prior to and ending eighteen (18) months after the occurrence of a Change in Control, then (subject to timely executing and not revoking the Release Agreement (as defined in the employment agreement)) the Restricted Stock Units shall vest in full on the later to occur of such termination or the Change in Control. (See footnote 2) F2 · shares: (continued from Footnote 1 above) Unless otherwise defined herein, the terms used herein have the same defined meanings as in the Restricted Stock Unit Agreement. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 22:10 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 1,222 | $12.22 | $14,930.76 |
DisclosureSEC source: 0001209191-21-007801 · doc4.xml · nonDerivative · entry 1 AUERBACH ALAN H · CIK 0001358285 · Director · PRESIDENT AND CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,283,036 F1 · kind: The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.2101 to $12.2350, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.